Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Z-338 (acotiamide) in Functional Dyspepsia
2013-003342-16Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acotiamide in functional dyspepsia (FD), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety of acotiamide 100 mg TID. Started Jan 2014; status: completed.
02
Drugs
acotiamide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2013-003342-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003342-16.